IRWD Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -4.77% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 49.9%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat CorMedix, Inc.'s return on equity of 95.25%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $5.35, signalling upside risk potential of 46.18%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 108.38%. Given that CorMedix, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.172, which suggesting that the stock is 82.759% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $47.7M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 30.35x while CorMedix, Inc.'s PE ratio is 3.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.09x versus 2.40x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -4.77% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -301.29%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Nektar Therapeutics's return on equity of -327.67%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $5.35, signalling upside risk potential of 46.18%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 97.05%. Given that Nektar Therapeutics has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.172, which suggesting that the stock is 82.759% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $47.7M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 30.35x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.09x versus 67.95x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of -4.77% compared to Ironwood Pharmaceuticals, Inc.'s net margin of -1338.77%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Outlook Therapeutics, Inc.'s return on equity of --.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $5.35, signalling upside risk potential of 46.18%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $5.38 which suggests that it could grow by 1140.48%. Given that Outlook Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.172, which suggesting that the stock is 82.759% less volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.102, suggesting its less volatile than the S&P 500 by 89.777%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $47.7M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of -$1.2M. Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Outlook Therapeutics, Inc.'s net income of -$23.1M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 30.35x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.09x versus 55.44x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of -4.77% compared to Ironwood Pharmaceuticals, Inc.'s net margin of 40.17%. Ironwood Pharmaceuticals, Inc.'s return on equity of -- beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Ironwood Pharmaceuticals, Inc. has a consensus price target of $5.35, signalling upside risk potential of 46.18%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 44.5%. Given that Ironwood Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Ironwood Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. has a beta of 0.172, which suggesting that the stock is 82.759% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Ironwood Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ironwood Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ironwood Pharmaceuticals, Inc. quarterly revenues are $47.7M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Ironwood Pharmaceuticals, Inc.'s price-to-earnings ratio is 30.35x while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals, Inc. is 2.09x versus 2.33x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.